Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (BNTX)
This is the main Biontech stock price chart and current quotes. You can find more details about BNTX stock by going to one of our multiple sections under this page such as historical data, price charts, technical analysis and others.
104.68
+2.87(+2.82%)
Closed·
Pre Market
105.93+1.25(+1.19%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
101.24
105.20
52 wk Range
76.53
131.49
BNTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 12 days
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
101.24105.20
52 wk Range
76.53131.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BNTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
142.65
Upside
+36.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Novavax stock tumbles on HHS comments about vaccine
- Investing.com
- 1
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novavax stock tumbles on HHS comments about vaccine
- Investing.com
- 1
- Barbara Weber, M.D., Elected to I™ Supervisory Board
- Investing.com
BioNTech SE Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BioNTech SE SWOT Analysis
Market Outlook | Analysts set price targets ranging from $125 to $130, reflecting cautious optimism about BioNTech's oncology potential and financial health |
Vaccine Legacy | COVID-19 vaccine business continues to generate substantial revenue, funding BioNTech's transition into a diversified biotechnology powerhouse |
Financial Fortitude | $18 billion cash reserves and positive cash flow provide BioNTech with stability and flexibility for R&D investments and strategic acquisitions |
Oncology Ambitions | BioNTech aims for 10 new approvals by 2030, with promising results in lung and breast cancer trials showcasing its ambitious oncology pipeline |
BioNTech SE Earnings Call Summary for Q4/2024
- BioNTech's Q4 EPS of $1.08 and revenue of $1.19B beat forecasts, yet stock fell 2.88% pre-market
- 2024 net loss of €665M, down from €930M profit in 2023; total revenue fell to €2.8B from €3.8B
- 2025 revenue projected at €1.7-2.2B; R&D expenses expected to be €2.6-2.8B
- Focus on oncology expansion, with multiple clinical data updates and potential regulatory submissions planned
- Strong cash position of €17.4B, but high R&D costs and negative EPS forecasts raise profitability concerns
Last Updated: 03/10/2025, 09:36 AM
Read Full TranscriptCompare BNTX to Peers and Sector
Metrics to compare | BNTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.0x | 0.0x | −0.5x | |
PEG Ratio | 0.19 | 0.01 | 0.00 | |
Price / Book | 1.1x | 0.9x | 2.6x | |
Price / LTM Sales | 8.0x | 3.0x | 2.9x | |
Upside (Analyst Target) | 37.8% | 252.1% | 64.0% | |
Fair Value Upside | Unlock | 26.1% | 9.4% | Unlock |
Analyst Ratings
17 Buy
4 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 142.65
(+36.28% Upside)
Earnings
Latest Release
Mar 10, 2025
EPS / Forecast
1.08 / 0.4767
Revenue / Forecast
1.19B / 1.12B
People Also Watch
FAQ
What Is the BioNTech (BNTX) Stock Price Today?
The BioNTech stock price today is 104.68
What Stock Exchange Does BioNTech Trade On?
BioNTech is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for BioNTech?
The stock symbol for BioNTech is "BNTX."
What Is the BioNTech Market Cap?
As of today, BioNTech market cap is 25.12B.
What is BioNTech Earnings Per Share?
The BioNTech EPS is -2.77.
What Is the Next BioNTech Earnings Date?
BioNTech will release its next earnings report on May 05, 2025.
From a Technical Analysis Perspective, Is BNTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.